摘要
【目的14g讨阿德福韦酯抗病毒治疗对乙型肝炎后性肝硬化患者IL—10及TNF-α的影响。【方法】选择乙肝肝硬化患者99例，按患者意愿分为阿德福韦酯治疗组（试验组）和一般治疗的对照组。试验组在一般治疗基础上加用阿德福韦酯口服，疗程48周。两组治疗前后用酶联免疫吸附法测IL-10，采用双抗体夹心酶联免疫分析法测定TNF-α，PCR法查HBV-DNA。【结果】试验组患者接受阿德福韦酯治疗后，Child—Pugh分级A、B级患者所占构成比及HBeAg、HBUDNA转阴率均明显高于对照组（P〈0．05）；与治疗前相比较，IL-10明显升高，TNF-α显著降低（P〈0．05），与对照组治疗后比较有显著差异（P〈0．05）。【结论】阿德福韦酯能有效抑制乙型肝炎病毒复制、修复肝脏功能、延缓肝硬化进程，可能与对血清IL-10和TNFn等细胞因子水平的调节，使患者免疫状态有所改善相关。
[Objective]To explore the effect of adefovir dipivoxil antiviral therapy on interleukin-10（IL- 10） and tumor necrosis factor alpha（TNF-a） in patients with post-hepatitis-B cirrhosis. [Methods] According to the willingness of the patients, 99 patients with post hepatitis-B cirrhosis were divided into adefovir dipivoxil therapy group（experimental group） and general treatment group （control group）. The experimental group was additionally given oral adefovir dipivoxil based on general treatment for 48 weeks. Enzyme linked immunosorbent assay was used to detect the level of IL 10 in two groups before and after treatment. Double antibody sandwich enzyme-linked immunosorbent assay was used to detect the level of TNF-α. PCR was used to meas ure HBV-DNA. [Results]After treatment with adefovir dipivoxil, the constitute ratio of the patients with Child Pugh classification A and B and the negative conversion rate of HBeAg and HBV-DNA in experiment group were significantly higher than those in the control group（ P 〈0.05）. Compared with before treatment, IL-10 increased significantly and TNF-a decreased significantly（ P 〈0. 05）. There was significant difference in the level of IL-10 and TNF-a between experimental group and control group after treatment（ P 〈0.05）. [Conclusion]Adefovir dipivoxil can effectively inhibit the replication of hepatitis B virus, restore liver function and delay the process of cirrhosis, which may be associated with its regulation for serum IL-10, TNF-α and other cytokines and the improvement of immune status of patients.
出处
《医学临床研究》
CAS
2011年第1期108-110,共3页
Journal of Clinical Research
